超声引导下经皮射频消融治疗卵巢成熟性囊性畸胎瘤的临床效果

Clinical effect analysis of ultrasound-guided percutaneous radiofrequency ablation in the treatment of ovarian mature cystic teratoma

目的探讨超声引导下经皮射频消融治疗卵巢成熟性囊性畸胎瘤的安全性及有效性。方法回顾性选取2020年5月至2023年5月郑州大学第一附属医院超声介入室诊治的卵巢成熟性囊性畸胎瘤患者35例,根据纳入标准最终23例行超声引导下经皮射频消融治疗的患者纳入本研究,观察患者治疗效果及术后1、3、6个月消融病灶的缩小率;观察术中、术后并发症的发生情况;对比患者术前,术后3 d及术后第1、3、6个月血清卵泡刺激素(FSH)、黄体生成素(LH)、雌二醇(E 2)、抗苗勒管激素(AMH)变化。结果23例患者均成功行射频消融治疗,完全消融率100%;术后1、3、6个月消融病灶的缩小率分别为(29.95±13.89)%、(51.45±17.62)%、(73.82±23.63)%;术中、术后均未出现严重并发症;手术前,术后3 d,术后1、3、6个月患者血清FSH、LH、E 2、AMH水平比较,差异无统计学意义(均P>0.05)。结论超声引导下经皮射频消融治疗卵巢成熟性囊性畸胎瘤是一种安全、微创、有效的治疗方法。

Objective To evaluate the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation in the treatment of ovarian mature cystic teratoma.Methods A total of 35 patients with mature cystic teratoma of the ovary diagnosed and treated in the ultrasound intervention room of the First Affiliated Hospital of Zhengzhou University from May 2020 to May 2023 were selected retrospectively.According to the inclusion criteria,23 patients who underwent ultrasound-guided percutaneous radiofrequency ablation were enrolled in this study,and the therapeutic effect and the reduction rate of the ablation lesions 1,3 and 6 months after surgery were observed.The occurrence of intraoperative and postoperative complications was observed.The changes of serum follicle stimulating hormone(FSH),luteinizing hormone(LH),estradiol(E 2)and anti-Mullerian hormone(AMH)were compared before surgery,3 days,and 1,3 and 6 months after surgery.Results All 23 patients underwent radiofrequency ablation successfully,and the complete ablation rate was 100%.The reduction rates were(29.95±13.89)%,(51.45±17.62)%and(73.82±23.63)%at 1,3 and 6 months,respectively.There were no serious complications during and after operation.There were no significant differences in serum levels of FSH,LH,E 2 and AMH before surgery,3 days,and 1,3 and 6 months after surgery(all P>0.05).Conclusions Ultrasound-guided percutaneous radiofrequency ablation is a safe,minimally invasive and effective treatment for ovarian mature cystic teratoma.